Amgen (AMGN) Takes Aim At Rare Disease Delays While Expanding RNA Drug Hunt

• Amgen (NasdaqGS:AMGN) announced a new collaboration with the National Organization for Rare Disorders to speed rare autoimmune disease diagnosis.

• The partners are targeting a goal to cut average diagnosis times for selected rare autoimmune conditions by 2036 through data and education efforts.

• Management also highlighted progress in Amgen's RNA-targeting small molecule discovery work, which uses AI tools to identify new drug candidates.

• The NORD rare autoimmune diagnosis push and Amgen RNA-targeting program both sit within a broader trend our research has been tracking. Check out 1 warning sign that Amgen investors should know about.

This type of healthcare AI adoption is not unique to Amgen, and there is a wider group of stocks exposed to similar trends 38 healthcare AI stocks .

Amgen is a US-based biotech group with a US$258.7b market cap that focuses on discovering and developing human therapeutics. Its work with NORD and RNA-targeting research both speak directly to how the business is trying to push complex disease treatment forward.

4 things going right for Amgen that this headline doesn't cover.

How does the NORD collaboration fit into Amgen's business model?

The NORD Learning Collaborative keeps Amgen close to care pathways in rare autoimmune disease, especially IgG4-Related Disease and Thyroid Eye Disease. Better mapping of referral patterns and diagnostic delays can inform how the group positions drugs like UPLIZNA and dazodalibep. For investors, this connects commercial execution directly to real world care gaps.

What does Amgen's RNA-targeting work mean for its competitive position?

Management is using AI tools to find small molecules that bind RNA, tying Amgen into an area where several large pharma groups are active. The goal is to discover oral drugs that hit targets traditionally handled by biologics. If that research feeds into late stage candidates, the pipeline could rely less on any single therapeutic area.

What should investors watch next to see if this thesis is working?

The next concrete check point is how rare disease and autoimmune assets show up in Amgen's reported numbers and disclosures through 2027, including any RNA-targeting molecules entering Phase 2 or Phase 3. Progress of the NORD pilot over its 14 month run will also indicate whether care pathway insights are translating into practical tools clinicians actually use.

The one Amgen question the headlines skip

News focuses on what Amgen is working on today, but analyst models already sketch out where the business could be a few years from now. Those projections tell a different story that deserves a closer look. See where analysts expect Amgen to be in a few years .